Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790481 | 0.81 | CHEK1 (0.43) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL13086601 | 0.78 | CCNB2 (0.41) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL3060533 | 0.77 | PARP1 (0.43) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3057285 | 0.77 | PNMT (0.43) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL7897594 | 0.77 | HPGD (0.36) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL3059839 | 0.77 | KDR (0.41) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| Hydrochloric Acid SCHEMBL3055083 | 0.76 | KDR (0.40) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| Hydrochloric Acid SCHEMBL3060187 | 0.76 | KDR (0.40) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| SCHEMBL3066815 | 0.75 | KDR (0.42) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| SCHEMBL7906040 | 0.75 | HPGD (0.34) | KDM4EALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | claimed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010077663-A2 | SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | CD274 904/4885TRPV3 3125/4885CNR2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.